AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for EGF domain-specific O-linked N-acetylglucosamine transferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q5NDL2

UPID:

EOGT_HUMAN

Alternative names:

Extracellular O-linked N-acetylglucosamine transferase

Alternative UPACC:

Q5NDL2; A8K2U1; B4DFH5; L7X1M5; Q6MZY0; Q6P985; Q6ZTV0

Background:

The EGF domain-specific O-linked N-acetylglucosamine transferase, also known as Extracellular O-linked N-acetylglucosamine transferase, plays a pivotal role in protein modification. It catalyzes the transfer of N-acetylglucosamine to serine or threonine residues in extracellular proteins, enhancing their function through O-GlcNAc linkage. This modification occurs specifically between the fifth and sixth conserved cysteines of folded EGF-like domains.

Therapeutic significance:

Linked to Adams-Oliver syndrome 4, a condition marked by congenital skin absence and limb defects, this protein's gene variants highlight its critical role in human health. Understanding the role of EGF domain-specific O-linked N-acetylglucosamine transferase could open doors to potential therapeutic strategies for managing and treating this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.